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osting by EAbstract In the present study a new acridone derivatives were synthesized. The newly synthesized
compounds were characterized by IR, NMR and C, H, N, S analyses. All newly synthesized com-
pounds were screened for their antibacterial (Staphylococcus aureus, Streptococcus viridans and
Escherichia coil) and antifungal (Gibberela, Cercospora arachidicola, Physolospora piricola and
Fusarium oxysporum) studies. The results revealed that all synthesized compounds have a signiﬁcant
biological activity against the tested microorganisms.
ª 2010 King Saud University. All rights reserved.1. Introduction
Chemical modiﬁcation of bioactive components is one of the
most common approaches in drug discovery with improved
therapeutic effect (Tan et al., 2006) and the wide occurrence
of the heterocycles in bioactive natural products and pharma-
ceuticals has made them as important synthetic targets.8921 5412; fax: +60 3 8921
mon).
ity. All rights reserved. Peer-
d University.
lsevierThe acridone alkaloid, acronycine, was isolated from Acr-
onychia baueri in 1948 and found to have potent anticancer
activity. A series of naturally occurring acridone alkaloids
were found to be potent molecules for inhibition of human
Promyelocytic leukemia cells (Singh et al., 2009; Fadeyi
et al., 2008). Glyfoline, another natural acridone alkaloid
isolated from Glycosmis citrifolia, was found to be the most
potent molecule for inhibition of human leukemic HL-60 cells
(Shoji et al., 2007). Several 9-acridone derivatives with or with-
out an alkyl side chain attached to the N-position were found
to exhibit anticancer and antibacterial activities reported in
vitro and in vivo anticancer activities of novel pyrimidoacri-
dones, pyridophenoxadines, and pyrimidocarbazones (Sondhi
et al., 2010) and suggested that anticancer topoisomerase II
inhibitors, such as amonaﬁde, amsacrine, doxorubicin, and
ellipticine contain a planar chromophore, which can interca-
late into the DNA helix. Pyrrolobenzodiazepine hybrid linked
to acridone ring system designed to exhibit signiﬁcant
206 J. Salimon et al.DNA-binding and shows promising in vitro anticancer activity
(Hagiwara et al., 2008). The triazoloacridones (C1305 and
C1533) showed potent antitumor activity towards a wide range
of different experimental tumors in vitro and in vivo, including
both murine and human colon carcinomas (Fig. 1). These
studies showed that the anticancer activity is due to DNA-
intercalation (Delmas et al., 2004). Later imidazoacridone
derivatives showed very good cytotoxicity against number of
human cancer cell lines. The most prominent analog, C1311,
is currently in clinical trials (Fig. 1). It has been found that
C1311 binds non-covalently to DNA to induce its cytotoxic ef-
fect (Boutefnouchet et al., 2010).
A series of 1-amino thioacridones were designed as DNA-
intercalating agents or DNA-intercalating agents with covalent
bond formation potential. Studies showed that one of the com-
pounds exhibited the most promising anticancer activity and
may be useful as a lead compound in the search for more po-
tent anticancer agents (Hegde et al., 2004).
On the other hand, 1,3,4-oxadiazole is a versatile lead mol-
ecule for designing potential bioactive agents. The 1,3,4-oxadi-
azole derivatives have been found to exhibit diverse biological
activities such as antimicrobial, (El-Emam et al., 2004;
Ku¨c¸u¨kgu¨zel et al., 2002), antiviral (Ku¨c¸u¨kgu¨zel et al., 2006),
anti-malarial (Akhter et al., 2009), analgesic (Unangast et al.,
1992), anti-inﬂammatory (Khan et al., 2001), anti-convulsant
(Kumar et al., 2008), hypoglycemic (Maslat et al., 2002) and
other biological properties such as genotoxic studies (Farghaly
et al., 2000) and lipid peroxidation inhibitor (Cao et al., 2003).
Keeping in view of these and in continuation of our research
on biologically active molecules, we hereby report the synthesis
of some acridone derivatives using Ullmann condensation be-
tween 2-chlorobenzoic acid and 2-aminobenzoic acid followedN
N
N
N
N
N
HO
O HN N
HO
O HN
C1305
C1311
Figure 1 Examples of antituby Friedel–Crafts acylation then screened all synthesized com-
pounds for there in vivo antimicrobial activities.
2. Experimental
2.1. Measurements
The percentage compositions of the elements (CHNS) for the
compounds were determined using an elemental analyzer
CHNS Model Fison EA 1108. The infrared spectra were
recorded as potassium bromide disks using a Perkin–Elmer
spectrophotometer GX. The 1H and 13C nuclear magnetic res-
onance spectra were recorded using the JEOL JNM-ECP 400
spectrometer. The purity of the synthesized compounds was
checked by TLC silica gel coated plates obtained from Merck
as stationary phase and solvent mixture of ethylacetate/chloro-
form as mobile phase at 25 C.
2.2. Synthesis
2.2.1. Synthesis of diphenylamine-2,40-dicarboxylic acid 1
To a mixture of 2-chlorobenzoic acid (12.5 g, 0.08 mol), 4-ami-
nobenzoic acid (10.97 g, 0.08 mol) and copper oxide powder
(0.2 g) in (60 ml) of amyl alcohol, dry potassium carbonate
(12 g) was slowly added and the mixture was allowed to reﬂux
for 6 h at about (100 C). The amyl alcohol was removed by
rotary evaporator then mixture poured into (250 ml) of hot
water, cooling and acidiﬁed with concentrated hydrochloric
acid. The greenish black precipitate which formed was ﬁltered,
washed with cold water and collected. The crude acid was dis-
solved in aqueous sodium hydroxide solution, boiled in the
presence of activated charcoal and ﬁltered, on acidiﬁcationN
N
N
HO
O HN
N
N
C1533
mor acridone derivatives.
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cipitate of 1 was obtained which was washed with water and
recrystallized from ethanol. Yield 78%, Rf 0.75, m.p. 208–
210 C. IR (KBr) t= 3453 (2O–H), 3367 (N–H), 3097 (C–H
aromatic), 1702 (C‚O), 1560 (C‚C). 1H NMR (DMSO-d6)
d= 8.02–8.07 (d, 1H, Ar-H), 8.0–7.95 (d, 1H, Ar-H), 7.65–
7.87 (d, 1H, Ar-H), 7.54–7.60 (d, 1H, Ar-H), 7.43–7.50 (d,
1H, Ar-H), 7.37–7.48 (d, 1H, Ar-H), 7.25–7.31 (d, 1H, Ar-
H), 7.18–7.22 (t, 1H, Ar-H), 7.09–7.14 (t, 1H, Ar-H), 8.87 (s,
1H, N–H) (D2O exchange, disappear), 9.05 (s, 1H, O–H)
(D2O exchange, disappear).
13C NMR (DMSO-d6)
d= 130.56–136.78 (12C, aromatic carbons), 173.47, 174.13
(2C, 2C‚O). Elemental analysis (C14H11NO4); calcd. C,
65.37; H, 4.31; N, 5.44; Found C, 65.43; H, 4.12; N, 5.89%.
2.2.2. Synthesis of 9(10H)-acridone-2-carboxylic acid 2
Compound 1 (5 g, 0.03 mol) was placed in a round bottom
ﬂask then it will add to concentrated sulfuric acid (25 ml), sha-
ken well and heated on water bath at (100 C) for 3 h. Appear-
ance of yellow color indicated the completion of the reaction.
Then, it was poured into hot water (150 ml). The yellow pre-
cipitate which formed was ﬁltered, washed with water and col-
lected. The sample of 9(10H)-acridone-2-carboxylic acid 2 was
recrystallized from methanol (Goodell et al., 2006). Yield 90%,
Rf 0.62, m.p. > 330 C. IR (KBr) t= 3427 (O–H), 3363 (N–
H), 3068 (C–H aromatic), 1705, 1685 (2C‚O), 1573 (C‚C).
1H NMR (DMSO-d6) d= 8.12–8.18 (d, 1H, Ar-H), 7.95–
8.02 (d, 1H, Ar-H), 7.54–7.65 (d, 1H, Ar-H), 7.52–7.64 (d,
1H, Ar-H), 7.25–7.32 (d, 1H, Ar-H), 7.24–7.27 (d, 1H, Ar-
H), 7.16–7.21 (t, 1H, Ar-H), 7.05–7.12 (t, 1H, Ar-H), 8.67 (s,
1H, N–H) (D2O exchange, disappear), 9.13 (s, 1H, O–H)
(D2O exchange, disappear).
13C NMR (DMSO-d6)
d= 131.23–135.97 (12C, aromatic carbons), 172.13, 174.65
(2C, 2C‚O). Elemental analysis (C14H9NO3); calcd. C,
70.29; H, 3.79; N, 5.86; Found C, 70.43; H, 3.02; N, 5.24%.
2.2.3. Synthesis of 9(10H)-acridonyl chloride 3
A mixture of (1 g, 0.004 mol) 9(10H)-acridone-2-carboxylic
acid 2 and excess thionyl chloride (10 ml) was reﬂuxed for
3 h, the excess of thionyl chloride was concentrate through
high vacuum, the residue was quenched with ice and the solid
separated was ﬁltered and dried through pump to afford title
compound 3 as white solid (Goodell et al., 2006). Yield
75%, Rf 0.53, m.p. 234–236 C. IR (KBr) t= 3346 (N–H),
3027 (C–H aromatic), 1685, 1673 (2C‚O), 1560 (C‚C). 1H
NMR (DMSO-d6) d= 8.34–8.39 (d, 1H, Ar-H), 8.23–8.31
(d, 1H, Ar-H), 8.20–8.27 (d, 1H, Ar-H), 8.13–8.19 (d, 1H,
Ar-H), 7.88–7.97 (d, 1H, Ar-H), 7.62–7.78 (d, 1H, Ar-H),
7.53–7.59 (t, 1H, Ar-H), 7.43–7.50 (t, 1H, Ar-H), 8.79 (s, 1H,
N–H) (D2O exchange, disappear).
13C NMR (DMSO-d6)
d= 132.76–137.11 (12C, aromatic carbons), 169.67, 172.45
(2C, 2C‚O). Elemental analysis (C14H8ClNO2); Calcd. C,
65.26; H, 3.13; N, 5.44; Found C, 65.14; H, 3.20; N, 5.37%.
2.2.4. Synthesis of 9(10H)-acridone-2-methylcarboxylate 4
To 9(10H)-acridone-2-carboxylic acid 3 (0.5 g, 0.00194 mol),
cold methanol (10 ml) was added readily and an instantaneous
reaction occurred to give the title product. The crystals of ester
were collected, ﬁltered and washed with cold solution of 10%
NaHCO3, then with cold water (Goodell et al., 2006). Yield
83%, Rf 0.67, m.p. > 340 C. IR (KBr) t= 3378 (N–H),
3024 (C–H aromatic), 1712, 1680 (C‚O), 1567 (C‚C). 1HNMR (DMSO-d6) d= 3.88 (s, 3H, –OCH3), 8.08–8.12 (d,
1H, Ar-H), 8.03–8.09 (d, 1H, Ar-H), 7.87–7.94 (d, 1H, Ar-
H), 7.78–7.83 (d, 1H, Ar-H), 7.74–7.79 (d, 1H, Ar-H), 7.66–
7.70 (d, 1H, Ar-H), 7.53–7.62 (t, 1H, Ar-H), 7.41–7.49 (t,
1H, Ar-H), 8.56 (s, 1H, N–H) (D2O exchange, disappear).
13C NMR (DMSO-d6) d= 22.14–23.32 (1C, –OCH3),
133.53–139.02 (12C, aromatic carbons), 170.31, 174.86 (2C,
2C‚O). Elemental analysis (C15H11NO3); calcd. C, 71.14; H,
4.38; N, 5.53; Found C, 71.79; H, 4.09; N, 5.78%.
2.2.5. Synthesis of 9(10H)-acridone-2-carboxylicacid
hydrazide 5
A mixture of 9(10H)-acridone-2-methylcarboxylate 4 (0.5 g,
0.00197 mol) and hydrazine hydrate (10 ml, 0.00591 mol) was
reﬂuxed for 3 h, then DMSO (1 ml) was added and the reﬂux
continued for another 24 h. The crude product was obtained
after distilling off the excess DMSO. Cooling ﬁltering then
washing with a little cold water, this product was employed
in the next step without further puriﬁcation. Yield 64%, Rf
0.82, m.p. 318–320 C. IR (KBr) t= 3347–3256 (NHNH2),
3024 (C–H aromatic), 1683, 1660 (2C‚O), 1558 (C‚C). 1H
NMR (DMSO-d6) d= 8.17–8.23 (d, 1H, Ar-H), 8.05–8.12
(d, 1H, Ar-H), 7.97–7.85 (d, 1H, Ar-H), 7.76–7.81 (d, 1H,
Ar-H), 7.65–7.70 (d, 1H, Ar-H), 7.45–7.53 (d, 1H, Ar-H),
7.27–7.34 (t, 1H, Ar-H), 7.15–7.23 (t, 1H, Ar-H), 8.56 (s, 1H,
N–H) (D2O exchange, disappear), 8.76 (s, 2H, NH2) (D2O ex-
change, disappear). 13C NMR (DMSO-d6) d= 131.80–136.73
(12C, aromatic carbons), 171.85, 174.60 (2C, 2C‚O). Elemen-
tal analysis (C14H11N3O2); calcd. C, 66.40; H, 4.38; N, 16.59;
Found C, 66.78; H, 4.67; N, 16.13%.
2.2.6. Synthesis of 2-[5-thiol-1,3,4-oxadiazol-2-yl]-9(10H)-
acridone 6
To a stirred mixture of 9(10H)-acridone-2-carboxylicacid
hydrazide 5 (0.5 g, 0.00169 mol) in ethanol (10 ml) and potas-
sium hydroxide (0.0946 g, 0.00169 mol), carbon disulﬁde
(0.202 ml, 0.00338 mol) was added slowly at (0 C), and the
mixture was reﬂuxed for 24 h. The solvent was evaporated
and the residue dissolved in water and acidiﬁed with dilute
hydrochloric acid. The precipitate was ﬁltered and washed
with little cold water. The crude product was recrystallized
from ethanol to give the desired product. Yield 87%, Rf
0.69, m.p. > 340 C, IR (KBr) t= 3335 (N–H), 3062 (C–H
aromatic), 2586 (S–H), 1678 (C‚O), 1552 (C‚C), 1332
(C‚S), 1057 (C–O oxadiazole ring). 1H NMR (DMSO-d6)
d= 5.23–5.26 (s, 1H, S–H) (D2O exchange), 8.10–8.16 (d,
1H, Ar-H), 7.78–7.81 (d, 1H, Ar-H), 7.57–7.64, 7.43–7.55,
7.36–7.40 (d, 1H, Ar-H), 7.27–7.33 (d, 1H, Ar-H), 7.20–7.24
(d, 1H, Ar-H), 7.15–7.18 (d, 1H, Ar-H), 7.09–7.12 (t, 1H,
Ar-H), 7.00–7.06 (t, 1H, Ar-H), 8.64 (s, 1H, N–H) (D2O ex-
change, disappear). 13C NMR (DMSO-d6) d= 53.12–54.96
(2C, –C–O–C– oxadiazole), 130.79–135.68 (12C, aromatic car-
bons), 169.98 (1C, C‚O). Elemental analysis (C15H9N3O2S);
Calcd. C, 61.01; H, 3.07; N, 14.23; S, 10.86; Found C, 61.13;
H, 3.51; N, 14.26; S, 10.92%.
2.3. Antimicrobial tests
All the newly synthesized compounds were evaluated for their
in vitro antibacterial activity against Staphylococcus aureus,
Streptcoccus viridans and Escherichia coli. Disk diffusion
method (Cruickshank et al., 1975; Collins 1976) was used for
Table 1 Antibacterial and antifungal data for the synthesized compounds.
Comp. no. Antibacterial activity data in MIC
(lg/mL)
Antifungal activity data in MIC (lg/mL)
S. aureus S. viridans E. coli Gibberela C. arachidicola P. piricola F. oxysporum
1 13 14 13 34 52 14 37
2 15 17 26 45 23 67 53
3 26 18 13 56 34 47 62
4 34 29 17 15 22 38 56
5 20 22 20 66 56 17 34
6 21 36 27 19 29 50 64
Ampicillin trihydrate (std.) 16 5 21 23 12 10 34
Fluconazole (std.) 38 32 27 15 29 26 31
DMF (control) – – – – – – –
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measuring 6.25 mm in diameter were punched from Whatman
no. 1 ﬁlter paper. Batches of 100 disks were dispensed to each
screw-capped bottle and sterilized by dry heat at 140 C for an
hour. The test compounds were prepared with different con-COOH
Cl
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H2N
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C
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OMe
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H
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Scheme 1 Reagents and conditions: (i) CuO/K2CO3, (ii) H2SO4/D, (ii
(vi) CS2, KOH, EtOH, reﬂux 24 h.centrations using DMF. One milliliter containing 100 times
the amount of chemical in each disk was added to each bottle,
which contained 100 disks. Disks of each concentration were
placed in triplicate in nutrient agar medium seeded with fresh
bacteria separately. The incubation was carried out at 37 CCOOH
N
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Solvent and growth controls were kept and zones of inhibition
were noted. The MIC (lg/mL) values of the tested compounds
against the tested bacteria strains are recorded in Table 1.
On the other hand, the newly prepared compounds were
screened for their in vitro antifungal activity against Cibberela,
Cercospora arachidicola, Physolospora piricola and Fusarium
oxysporum in DMSO by the serial plate dilution method
(Khan, 1997; Varma, 1998). All the fungal strains were clinical
isolates, identiﬁed with conventional morphological and bio-
chemical methods. Fluconazole (antifungal) was used as refer-
ence drug. Sabouraud’s agar media were prepared by
dissolving peptone (1 g), D-glucose (4 g), and agar (2 g) in dis-
tilled water (100 ml) and adjusting the pH to 5.7. Normal sal-
ine was used to make a suspension of the spore of fungal strain
for lawning. A loopful of particular fungal strain was trans-
ferred to 3 ml saline to get a suspension of the corresponding
species. Agar media (20 ml) was poured into each petri dish.
Excess suspension was decanted and the plates were dried by
placing in an incubator at 37 C for 1 h. Using an agar punch
wells were made into each well labeled. A control was also pre-
pared in triplicate and maintained at 37 C for 3–4 days. Anti-
fungal activity was determined by measuring the diameter of
the inhibition zone. The MIC (lg/mL) values of the tested
compounds against the tested fungal strains are recorded in
Table 1.
3. Results and discussions
3.1. Chemistry
Ullmann condensation of 2-chlorobenzoic acid with 4-amino-
benzoic acid was carried out by reﬂuxing the reactants in the
presence of copper oxide and potassium carbonate in amyl
alcohol medium afforded diphenylamine-2,40-dicarboxylicacid 1. In this reaction as copper catalyzed nucleophilic
aromatic substitution on aryl halide bearing electron
withdrawing group. Further this dicarboxylic acid was con-
verted into 9(10H)-acridone-2-carboxylic acid 2, by reacting
with conc. sulfuric acid (Goodell et al., 2006). Title compound
2-[5-thiol-1,3,4-oxadiazol-yl]-9(10H)-acridone 6 was synthe-
sized by reﬂuxing equimolar mixture of 9(10H)-acridone-
2-carboxylicacid hydrazide 5 with potassium hydroxide and
excess of carbon disulﬁde in ethanol (10 ml) for 6 h
(Scheme 1).
The suggested mechanism of 2-[5-thiol-1,3,4-oxadiazol-2-
yl]-9(10H)-acridone 6 is depicted in Scheme 2.
3.2. Characterization of the synthesized compounds
The structures of the resulting compounds were established by
elemental analysis, IR and NMR. The proposed structure gi-
ven to 9(10H)-acridone-2-carboxylicacid hydrazide 5 was sup-
port by IR analysis which showed band at 3347–3256 cm1
due to stretching vibration of NHNH2 moiety (Silverstien
et al., 2005). Its 1H NMR spectrum showed two D2O
exchangeable signal at 8.56 and 8.76 ppm assignable for the
NHNH2 moiety. Furthermore, the
13C NMR spectrum
showed two C‚O signals at 171.85 and 174.60 ppm.
Formation of 2-[5-thiol-1,3,4-oxadiazol-yl]-9(10H)-acri-
done 6 was conﬁrmed by recording its IR, NMR and elemental
analysis. IR spectrum of compound 6 showed absorption at
3097 cm1 due to the aromatic stretching. An absorption band
at 1594 cm1 assignable for C‚N group, band at 1057 cm1 is
due to stretching of oxadiazole ring and the absorption band
appeared at 664 cm1 is for C–S group (Fuloria et al., 2009).
The 1H NMR spectrum of 6 showed multiplet in the region
of d 8.07–7.00 assignable to aromatic protons. Similarly a sin-
glet appeared at d, 5.03 due to the one proton of the S–H
group (Jayashankar et al., 2009).
210 J. Salimon et al.3.3. Antimicrobial studies
All the newly synthesized compounds were screened for their
antibacterial and antifungal activity. For antibacterial studies
microorganisms employed were S. aureus, Streptococcus
viridans and Escherichia coil. For antifungal, Gibberela, C.
arachidicola, P. piricola and F. oxysporum were used as micro-
organisms. Both antimicrobial studies were assessed by mini-
mum inhibitory concentration (MIC). The data are
summarized in Table 1, and show that all compounds display
certain activity against the tested microorganisms.
From SAR we can see that the antibacterial and antifungal
activity of the synthesized compounds may be due the presence
of the versatile pharmacophore which might increase the lipo-
philic character of the molecules, which facilitate the crossing
through the biological membrane of the microorganism and
thereby inhibit their growth.
4. Conclusion
The preparation procedure follow in this work for synthesis of
the title compounds offers reduction in the reaction time, oper-
ation simplicity, cleaner reaction, easy work-up and improved
yields. All spectroscopic analysis conﬁrmed the proposed
structures of these compounds. Biological activity data have
shown that the synthesized compounds have a signiﬁcant bio-
logical activity against the tested microorganisms.Acknowledgements
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